Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

230.09B

Market cap230.09B

Price-Earnings ratio

25.84

Price-Earnings ratio25.84

Dividend yield

2.64%

Dividend yield2.64%

Average volume

2.52M

Average volume2.52M

High today

$397.28

High today$397.28

Low today

$391.80

Low today$391.80

Open price

$395.63

Open price$395.63

Volume

150.82K

Volume150.82K

52 Week high

$398.00

52 Week high$398.00

52 Week low

$269.77

52 Week low$269.77

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $397.24. The company's market cap stands at 230.09B, with a P/E ratio of 25.84 and a dividend yield of 2.64%.

During the trading session on 2026-07-29, Amgen(AMGN) shares reached a daily high of $397.28 and a low of $391.80. At a current price of $397.24, the stock is +1.4% higher than the low and still -0.0% under the high.

Trading activity shows a volume of 150.82K, compared to an average daily volume of 2.52M.

The stock's 52-week range extends from a low of $269.77 to a high of $398.00.

AMGN News

Simply Wall St 2h

Amgen Stock Could Be A Bargain On Cash Flow But Fairly Priced On Earnings

Amgen stock has delivered an 88.5% total return over the past five years, and the latest Discounted Cash Flow (DCF) estimate currently points to the shares trad...

Nasdaq 2h

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Key Points Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task. Its competitors are...

TipRanks 5h

Amgen price target raised to $360 from $350 at Barclays

Barclays analyst Emily Field raised the firm’s price target on Amgen (AMGN) to $360 from $350 and keeps an Equal Weight rating on the shares. The firm adjusted...

Analyst ratings

49%

of 35 ratings

Buy

40%

Hold

48.6%

Sell

11.4%

More AMGN News

Investing.com 1d

Amgen stock hits all-time high at 391.3 USD - Investing.com

...

TipRanks 2d

Amgen Halts Key Phase 3 Rocatinlimab Study, Resetting Expectations in Dermatology

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Simply Wall St 3d

Amgen Beat Revenue Forecasts, Is The Stock Overvalued?

Amgen (AMGN) is back in focus after quarterly revenue of $8.62b surpassed analyst forecasts, with management pointing to double digit growth across 16 brands an...

Simply Wall St 6d

What Amgen's Blocked Colorado Enbrel Price Cap Means For Shareholders

Earlier in July 2026, a federal judge blocked Colorado’s plan to impose a very large price cut on Amgen’s arthritis drug Enbrel, halting one of the most aggress...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.